Emergency department interventions for smoking cessation: a systematic review and meta-analysis
Abstract
Background: Emergency departments (EDs) offer a valuable opportunity to intervene to support people to quit smoking. We sought to determine the effectiveness of smoking cessation interventions delivered in the ED setting on rates of abstinence at the longest follow-up.
Methods: We undertook a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines considering only randomised controlled trials (RCTs), based in the ED, where the goal of the intervention was smoking cessation and follow-up was at least 3 months. We systematically searched electronically published literature and trial registries from inception to May 2025. We pooled data using a Mantel-Haenszel random-effects model for behavioural interventions without pharmacotherapy, and using a fixed-effects model for interventions incorporating nicotine replacement therapy (NRT), with results reported as risk ratios (RR) and 95% CIs. The primary outcome was smoking cessation using the strictest available measure, biochemically validated where possible. Risk of bias was assessed using the Cochrane risk of bias tool. Certainty of overall evidence was assessed using GRADE (Grading of Recommendations, Assessment, Development and Evaluation).
Results: Nineteen RCTs met inclusion criteria, of which 17 were deemed suitable for incorporating into meta-analyses. Participants randomised to receive a smoking cessation intervention involving NRT in the ED were significantly more…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 4,711 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.